Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)

[at noodls] – ROCKVILLE, Md., Nov. 19, 2012 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that it has received confirmation from the Food and Drug … more

View todays social media effects on SUPN

View the latest stocks trending across Twitter. Click to view dashboard